Background: AlphaIIb/beta3 (αIIb/β3) complex is an important integrin that is involved in the fi nal step of platelet aggregation. Peptides derived from either αIIb or β3 have demonstrated to have an effect on the activation of the complex and its ability to bind fi brinogen. We have previously defi ned a peptide from β3, which inhibits agonists-induced platelet aggregation.
Introduction
AlphaIIbbeta3 (αIIb/β3) complex plays an important role in platelet aggregation. The αIIb/β3 complex exists in the inactive and active conformational states. The activated complex serves as ligand-binding sites (Luo et al. 2004; Schwartz et al. 1995) for four macromolecules (fi brinogen, von Willebrand factor, fi bronectin and vitronectin). The binding of fi brinogen to the activated αIIb/β3 complex mediates the fi nal step of platelet aggregation. In damaged vessel walls, αIIb/β3 undergoes a conformational change from an inactive to an active state that is able to initiate thrombi formation.
Many studies have proposed that the interaction between αIIb and β3 reside in several regions (Filizola et al. 2004; Feuston, 2003 and D'Souza et al. 1994 ). There are two discrete peptides defi ned from β3 with amino acid residues of 211-222 and 217-230, which have been reported to inhibit fi brinogen binding and affect platelet aggregation (Charo et al. 1991 and Steiner et al. 1993) . In addition, two complex forming sequences of αIIb and β3 (αIIb: 94-314 and ß3: 118-131, and αIIb: E117 and β3:R214), which correlate with both ligand and cation binding within the αIIb/β3 complex, have been identifi ed (Feuston, 2003; D'Souza et al. 1994; D'Souza et al. 1991 and Charo et al. 1991) .
Other investigators (Kashiwagi et al. 1999; Sun et al. 2002; Beglova et al. 2002 and Butta et al. 2003) have addressed the important function of cysteine residues in β3. The consensus is that cysteine residues play an important role in the formation of the active complex. Wang et al. (1997) have found that disruption of the disulfi de bond between Cys 406 and Cys 665 of β3 did not affect αIIb/β3 ligand binding. However, in some cases, disruption of certain disulfi de bonds resulted in the formation of an active complex. Kashiwagi et al. (1999) created a single amino acid mutation in the extracellular cysteine-rich repeat region of the β3 subunit (T562N), and activated αIIb/β3. Although, many laboratories have studied the extracellular, transmembrane, cytoplasmic regions and carboxylterminal of β3 in relation to the formation of the functional complex, the exact site remains to be determined.
Previously, we have reported that a platelet 90-kDa glycoprotein (GP 90) is involved in collagen-, epinephrine-, and thrombin-platelet interaction (Chiang et al. 1989) . We have identified the protein as β3 by using twodimensional gel (2D gel) electrophoresis, immunblotted with anti-90-kDa and anti-β3 antibodies, and Matrix Assisted Laser Desorption/ Ionization-Time of Flight (MALDI-TOF). Searches of the SWISS-PROT database for the identity with the mass spectra of the trypsinized fragments, isoelectric point, and molecular weight resulted in a match with human platelet β3. Recently, we have defi ned a region of β3 (residues 499-513, named P4), which inhibits antagonists-induced platelet activation by inhibiting FITC-PAC-1 binding. A chemically synthesized peptide also inhibits ADP-, type I collagen-and type III collagen-induced platelet aggregation in a dose-dependent manner through the inhibition of αIIb/β3 complex formation (Chiang et al. 2005) .
In the present study, we have constructed three mutant cDNAs of β3 by scrambling the amino acid residues and the other two by substituting the cysteine residues with alanine (C499A and C512A) of the P4 peptide region and expressing them with wild type αIIb, as well as expressing αIIb/β3-wild type in Chinese hamster ovary cells (CHO). We examined the binding ability of the mutant compared with wild type to FITC-PAC-1 and [
3 H]-fi brinogen. Results show that co-transfection with the mutated cDNAs expresses an inactive complex and binds less FITC-PAC-1 as compared to wild type. In addition, a chemically synthesized peptide (of the defi ned region) inhibited the binding of FITC-PAC-1 as well as inhibiting the binding of [ 3 H]-fibrinogen onto Mn 2+ -activated wild type αIIb/β3 expressed in CHO cells. These results suggest that the P4 peptide of β3 and its cysteine residues play an important role in the formation of the active complex of αIIb/β3.
Material and Methods

Reagents
Monoclonal anti-β3 was purchased from R&D systems, Inc. (Minneapolis, MN) and monoclonal anti-αIIb (clone SZ22) was purchased from Beckman Coulter (Fullerton, CA). The monoclonal antibody, which recognizes the inactive complex of αIIb/β3, AP2, was purchased from GTI Diagnostics (Waukesha, WI). The Chinese hamster ovary (CHO-K1) cell line was purchased from America Type Culture Collection (ATCC) (Manassas, VA 
Preparation of platelet-rich plasma (PRP)
Human blood (9 parts) from normal volunteers, were collected following an overnight fast, in polypropylene tubes containing 1 part 3.8% sodium citrate. PRP was prepared by centrifuging the citrated blood at room temperature for 10 minutes at 226 × g (Chiang et al. 1976) . Whole blood and PRP were exposed to plastic surfaces or siliconized vessels only. Platelet counts of the PRP ranged from 200,000 to 300,000 per mm 3 . The washed platelets for binding assays were prepared by gently mixing equal volumes of PRP and 20 mM Tris-HCl-130 mM NaCl-1 mM EDTA, pH 7.4 (Tris-EDTA), centrifuged at 1,000 × g for 5 min, washed once with Tris-EDTA and then resuspended in the Tyrode's buffer.
Binding of [ 3 H]-fi brinogen to washed human platelets
Fibrinogen was labeled with [
3 H]-formaldehyde as described by others (Whitnack et al. 1985; Rice et al. 1971 and Grinnell, 1980) . Briefl y, human fibrinogen was dissolved in PBS at a concentration of 3.4 mg of clottable protein per ml (10 µM), dialyzed against PBS to remove salts, and stored at -20 °C. Fibrinogen was dissolved in 0.2 M sodium borate (pH 7.4) at a concentration of 10 µM and dialyzed against the same buffer. The fi brinogen was then subjected to reductive N-methylation at 4 °C with 0.1 volume of a 1% aqueous solution of [ 3 H]-formaldehyde, followed by 0.3 volume of sodium borohydride. The labeled fibrinogen was dialyzed against PBS, assessed for amount of bound radiolabel, assayed for binding capacity and fi nally, stored at −20 °C.
The binding mixture consisted of washed human platelets (10 8 ) in Tyrode's buffer (5 mM HEPES, 2 mM MgCl 2, 0.3 mM NaH 2 PO 4 , 3 mM KCl, 12 mM NaHCO 3 , 0.1% glucose, 0.1% BSA, and 1 mM CaCl 2 , pH 7.0). Various amounts of P4 and scrambled P4s peptides (0-80 µM) were used to determine the dose response of inhibition of binding by fi brinogen for 30 minutes at room temperature. Initiation of the assay began with the addition of ADP (final concentration of 0.5 µM), incubated at room temperature for 5 minutes, followed by adding [ 
Construction and expression of wild type and mutant β3 cDNAs
Construction of a plasmid encoding for the fulllength cDNA of platelet β3 were from several cDNA fragments deposited at ATCC and subcloned into the vectors pET-24a and pcDNA3.1. The β3-mut cDNA is a scrambling of the peptide sequence from 499-513 (473-487 according to numbering by Kamata et al. 2001 ) of β3 by PCR. The two sets of primers used were, forward primer: 5'-ACA-GATCTTGCGAGTATTCCGAGCAGTGCCCCC-GGGAGGGTCAGCC-3 and reverse primer: 5'-CAAGATCTGTCGCTAGGCTGCTCGTCCT-CACACTGGGATCCCAGC-3'. The following primers were used to construct the cDNA with C499A using forward primer: 5'-GGATCCCAGT-GTGAGGCCTCAGAG-3' and reverse primer: 5'-CTCTGAGGCCTCACACTGGGATCC-3' and the second cDNA with C512A using forward primer: 5'-GCAGGACGAGGCCAGCCCCCGG-3' and reverse primer: 5'-CGGGGGCTGGCCTC-GTCCTGC-3'. The template used for all PCR reactions was β3-wild type in pcDNA3.1. All of the fi nal PCR products carrying the desired mutations in the full-length cDNA were treated with Dpn I, purifi ed, transformed into DH5α, selectively screened, and sequence verified before proceeding with expression.
Peptides for inhibition studies
The first chemically synthesized peptide is C(Acm)SEEDYRP SQQDEC(Acm)S, which we referred to as P4. The second chemically synthesized peptide is the scrambled version of P4, SDC (Acm)EYPESEQRSQDC(Acm), which served as a control and is referred to as P4s.
Establishment of stable cell lines for eukaryotic expression in CHO cells and immunoblot analyses
Wild type β3 or mutant β3 (β3-mut) (4 µg of each construct) and wild type αIIb (4 µg) were cotransfected into CHO cell using Lipofectamine 2000 according to the manufacturer's specifi cations. Cells were incubated 37 °C for 48 hours following transfection, allowing for transgene expression in selective media containing 700 µg/ml of Geneticin for two weeks. Selected single colonies were expanded to 24-well plates and the selected integrant was screened by fl ow cytometry in a BD FACS Calibur using the AP2 antibody conjugated to the fl uorescent dye (Alexa Fluor 647). Following selection, the cells are maintained in selective medium with 700 µg/ml of Geneticin. Immunoblot analysis with both, αIIb and β3 antibodies also verifi ed the successful co-transfections.
Flow cytometry analysis of activated of αIIb/β3 complex Stable cells (wild type αIIb/β3 and αIIb/β3-mut) were harvested with 0.5 mM EDTA/PBS pH 7.4, washed twice with 50 mM HEPES/1% glucose/2 mM Ca 2+ /2 mM Mg 2+ pH 7.4 (HEPES buffer I) and resuspended in 50 mM HEPES/1% glucose/ 1 mM Ca 2+ /1 mM Mg 2+ pH 7.4. (HEPES buffer II). Activation of the washed cells (1 × 10 6 /ml) were initiated by the addition of 2 mM Mn 2+ for 45 minutes (Litvinov et al. 2004) , then incubated with FITC-PAC-1 for an additional 60 minutes at room temperature. Following three washes with HEPES buffer II, the cells were resuspended in the same buffer and the amount of FITC-PAC-1 binding was analyzed by fl ow cytometry.
Inhibition of αIIb/β3 active complex by peptides
The chemically synthesized peptides, P4 and P4s, were used to determine whether they could inhibit the activation of the wild type αIIb/β3 complex. Again, cells were prepared as previously stated, incubated with varying amounts of peptide, (either P4 or P4s, 0-80µm) and 2 mM Mn 2+ for 45 minutes, followed by incubation with FITC-PAC-1 for an additional 60 minutes at room temperature. Following immunostaining, all cells were washed three times in HEPES buffer II, resuspended in the same buffer and binding was analyzed by fl ow cytometry. (Fig. 1, line with diamonds) . The percent inhibition by P4 is dose-dependent. Treatment with P4s did not signifi cantly reduce fi brinogen binding (Fig. 1, line with fi lled squares) . In addition, the P4 peptide could not inhibit the binding of fi brinogen to platelets without the addition of suboptimal concentrations of ADP (data not shown). These results suggest that the peptide probably binds on GP IIb to inhibit the αIIb/β3 active complex formation rather than directly affecting the fi brinogen binding to the activated complex.
Binding of [ 3 H]-fi brinogen to stable co-transfected CHO cells
In order to study the effects of P4 (wild type β3) on the formation of active αIIb/β3, we have engineered a construct containing the scrambled sequence of the active peptide (P4s) in β3 cDNA. It served as a control (named as β-mut) in cotransfection with wild type αIIb cDNA into CHO cells and proved that the P4 peptide is an inhibitor of αIIb/β3 active complex formation.
Recombinant proteins of αIIb, β3, and β3-mut expressed in CHO cells
Expressions of co-transfected proteins, αIIb with wild type-β3 or β3-mut were examined by immunoblot analyses. Figure 2 shows that both wild type αIIb and wild type β3 proteins and wild type αIIb and β3-mut were detected in co-transfected CHO cell lysates. Panels A and B shows a set of immunoblots of co-transfected CHO cells (lane 1: mock, lane 2: αIIb/β3 wild type, and lane 3: αIIb/β3-mut). The αIIb antibody recognized αIIb expressed in CHO cells expressing wild type αIIb/β3 (lane 2) and αIIb/β3-mut (lane 3) as shown in panel A (arrow). In addition, the β3 antibody recognized β3 proteins expressed in the wild type αIIb/β3 (lane 2) and less in αIIb/β3-mut (lane 3) as shown in panel B (arrow).
We have then used fl ow cytometry to study the αIIb/β3 expression in co-transfected CHO cells. Figure 3 , panel A showed the presence of an inactive complex, identifi ed by the AP2 antibody in both αIIb/β3 (line 2) and αIIb/β3-mut (line 3). The binding capacity of AP2 (calculated as percentage gated subset) was similar between wild type β3 and β3-mut. The mutation made in β3 did not interrupt the ability for the protein to be expressed, as well as being transported to the cell surface and forming the complex. Panel B showed that in the absence of Mn 2+ , the FITC-PAC-1 binding level (calculated as percentage gated subset) was also similar in both wild type (line 2) and αIIb/β3-mut expressed complexes (line 3). However, in panel C, following incubation with 2 mM Mn 2+ , the ability to bind FITC-PAC-1 increased in the αIIb/β3 wild type expressed complex (line 2) but not the αIIb/β3-mut expressed complex (line 3).
In addition to the wild type β3 and β3-mut, we have constructed two other mutants to examine the role of the cysteine residues within the peptide. We have performed replacement of cystine residues (499 and 512) one at a time with alanine. Table 1 shows following Mn 2+ treatment, the wild type αIIb/β3 had a higher percentage (92%) of PAC-1 binding, compared to a lower percentage with the αIIb/β3-mut (61%). Replacement of either 499 (89%) or 512 (91%) with Ala, the binding of PAC-1 did not change signifi cantly compared to wild type. The binding of PAC-1 by GP IIb/IIIa-C499A (89%) or GP IIb/IIIa-C512A (91%) did not change significantly compared to wild type. However, these results do indicate that Mn 2+ could not fully activate αIIb/β3-mutants resulting in fewer numbers of the formation of the active complex and thus less binding of FITC-PAC-1.
We have assayed and analyzed the effect of both the P4 and P4s peptides to the Mn 2+ -activated αIIb/β3 complex by measuring the binding of FITC-PAC-1. 28% (panel C, 60 µM) and 60% (panel D, 80 µM), respectively. The concentration of peptide required for inhibition was similar to that used in washed human platelets (Schwartz et al. 1995 (Fig. 5 , line with open circles), as the peptide dose increased, the amount of fi brinogen binding to the cell surface decreased. The scrambled peptide, P4s, did not inhibit the fi brinogen binding signifi cantly (Fig. 5 , line with fi lled squares), indicating that the order of amino acid residues in the P4 peptide sequence is important for inhibiting αIIb/β3 complex formation, thus inhibiting fi brinogen binding. Although, this experiment may not represent the cellular physiology and biochemistry of human platelets, it may be another useful tool to study the interaction processes. 
Discussion
We have previously defi ned a peptide (P4), amino acid residues from 499-513 of β3 as one of several important sites of the active conformational state of the complex αIIb/ß3 (Chiang and Zhu, 2005 (Chiang and Zhu, 2005) .
Collagen-induced platelet aggregation is mediated by the released of ADP from the collagen-activated platelets. In the present studies, we have used suboptimal concentrations of ADP to trigger partial platelet activation for the binding of [
3 H]-fi brinogen. However, under these same conditions, the addition of P4s does not inhibit the binding of [ 3 H]-fi brinogen. In contrast, the addition of P4 after platelets become fully activated, does not inhibit fi brinogen binding. The 2,3,5,6-tetrafl uorophenyl ester (purchased from Molecular Probes)-labeled P4 and P4s could not bind on the fi brinogen-coated wells. These fi ndings suggest that the peptide does not bind to fi brinogen per se to lower [ 3 H]-fi brinogen concentration in turn to decrease the binding. Parise et al. (1987) and Du et al. (1991) have reported that the RGD peptide (a recognition sequence for fibrinogen binding) or RGDderived peptides inhibit(s) the binding site exposed by conformational changes in platelets. Our results showed that P4 peptide inhibits the binding of both FITC-PAC-1 and [
3 H]-fi brinogen on the stably co-transfected Mn 2+ -activated αIIb/β3 complex. The dose-dependent inhibitory effect of P4 peptide indirectly leads us to postulate that the peptide binds to αIIb and prevents the formation of the active αIIb/β3 complex. Alternatively, P4 modifi es the αIIb/β3 complex conformation in some fashion to keep it in the inactive state. In our results, the peptide inhibitory effects are partial. A plausible explanation would be that there is more than one region involved in the activation of the complex formation. Our results would support Takagi's fi nding, in which he suggests a "2-site docking model" from his study of ligand recognition by RGDdependent integrins (Takagi, 2004) . Blystone et al. (1995) has reported that exposure to Mn 2+ shifts the β3 integrin to their high affi nity state and possibly activation of the receptor or the subsequent function of β3 following activation. In addition, Takagi et al. (2002) have reported that integrins, αVβ3 and αIIbβ3, have a highly bent conformation and had low affinity for biological ligands under physiological condition. The addition of Mn 2+ resulted in a switchblade-like opening to an extended structure that has high affinity for biological ligands. Our results are consistence with theirs in that upon exposure to Mn 2+ , the αIIb/β3 complex shifts from its inactive to the active state as shown by the increase in FITC-PAC-1 binding.
Cysteine residues in β3 play important roles in αIIb/β3 complex activation. Sun et al. (2002) reported that disruption of the long-range β3 Cys5-Cys435 disulfi de bond resulted in the production of constitutively active αIIb/β3 integrin complex. Another report proposed that the cysteine residues located from 616-690 of the carboxyl-terminal region was important in enhancing ligand binding (Butta et al. 2003) . Kashiwagi et al. (1999) found that disrupting only a single disulfi de bond in the cysteine-rich repeat region of β3 was enough to activate αIIb/β3. The P4 peptide, which we have identifi ed is present within the cysteine-rich region of β3 and contains two cysteine residues, which may form a disulfi de bond with other cysteines of αIIb. We used the DIpro 2.0 software to predict the location, which the disulfi de bond formation would reoccur (Cheng et al. 2006 ). According to the software results of proposed β3-mut, the predicted disulfi de bridge reforms at 513-527. Altering the positions of these two cysteine residues may affect the ability of Mn 2+ to activate αIIb/β3. The β3-mut cDNA we created and expressed in CHO cells was not clearly defi ned by Coomassie Brilliant blue stained SDS-PAGE or by immunoblot analysis with an anti-β3 monoclonal antibody (Fig. 1, panel B, lane3 ). However, with flow cytometry, we observed the presence of the inactive complex of αIIb/β3-mut with AP2 (an antibody, which recognizes the αIIb/β3 inactive complex). The percentage-gated subset of AP2 binding was similar between the two different stable lines αIIb/β3 and αIIb/β3-mut. These results indicate that expression and transport of the αIIb/β3-mut proteins to the cell surface does occur. The poor immunoblot result of β3-mut may be a consequence of the inability of the antibody to recognize the mutated sequence of amino acid residues. The αIIbβ3-mut cDNA expressed in CHO cells did not show strong activation of the inactive complex with the addition of Mn 2+ . Our results of substitution of C499A and C512A resulted in less PAC-1 binding suggesting these two cysteines are also important.
Integrins have become attractive therapeutic targets. Many drugs, which inhibit integrin αIIb/ β3 binding can effectively block agonists induced platelet aggregation in vitro. However, intravenous infusion or oral ingestion of these drugs failed to effectively block pathological thrombosis in certain patients. This raises a question of "How effective is the ligand-mimetic integrin blockade?" Our results demonstrates that the P4 peptide is important for interfering with αIIb/β3 activation, thus inhibiting binding of fi brinogen on activated platelets and platelet aggregation in vitro, may be another candidate as a therapeutic agent. However, its functional signifi cance in vivo is not clear and requires further investigation.
